de Liaño Lista AG, et al. - A retrospective analysis of urothelial carcinoma (UC) persons progressing to frontline or later-line anti–PD-1/PD-L1 therapy in ten European institutions was done between March 2013 and September 2017 in order to investigate the outcome of UC people who received subsequent systemic treatment (SST) and no SST following progressing to immune checkpoint inhibitors (ICIs). Two hundred and seventy UC persons with PD to ICIs (69 frontline, 201 later line) were assessed. It was found out that individuals progressing to frontline ICIs were at risk of early death, excluding them from experiencing possible advantage from chemotherapy.